Rockwell Medical, Inc. Earnings Recaps
Q3 2025
Nov 12, 2025
Rockwell Medical reported a profitable third quarter driven by strategic contract management and operational efficiencies, despite the anticipated impact from the transition of its largest customer.
Key takeaways
- Achieved adjusted EBITDA profitability while net sales reached $15.9 million, aligning with full-year guidance.
- Maintained gross margins within the targeted range of 16% to 18%, showcasing stability amid customer transitions.
- Secured multiple long-term purchasing agreements, including a notable contract with a Southern Florida dialysis center expected to generate approximately $1 million in annual net sales.
- Continued supply to former largest customer, who represented 12% of sales, highlighting ongoing demand and the challenges of supplier transitions in critical healthcare services.
- Strengthened contract portfolio with over 80% of customers now under long-term agreements, enhancing revenue visibility and stability for future growth.
Q2 2025
Aug 14, 2025
Rockwell Medical reported a 38% decline in net sales for Q2 2025, largely due to the transition of their largest customer to a new supplier, yet managed to maintain a positive cash flow from operations.
Key takeaways
- Net sales for Q2 2025 decreased to $16.1 million, down from $25.8 million in Q2 2024.
- Over 80% of customers are secured under long-term contracts, providing stability amidst a challenging transition year.
- The company achieved adjusted EBITDA improvement, reducing losses from a negative $400,000 in Q1 to negative $200,000 in Q2 2025.
- New multiyear agreements with significant clients show potential for revenue recovery in the coming quarters.
- Guidance for 2025 remains unchanged with expected net sales between $65 million and $70 million.